Cancer-related inflammation and Barrett’s carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett’s cells

Hui Ying Zhang,1 Qiuyang Zhang,1 Xi Zhang,1 Chunhua Yu,1 Xiaofang Huo,1 Edaire Cheng,2 David H. Wang,1,3 Stuart J. Spechler,1 and Rhonda F. Souza1,3

Departments of 1Medicine and 2Pediatrics, Veterans Affairs North Texas Health Care System, Children’s Hospital, and the University of Texas Southwestern Medical Center, Dallas; and 3The Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas

Submitted 7 October 2010; accepted in final form 3 December 2010

Zhang HY, Zhang Q, Zhang X, Yu C, Huo X, Cheng E, Wang DH, Spechler SJ, Souza RF. Cancer-related inflammation and Barrett’s carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett’s cells. Am J Physiol Gastrointest Liver Physiol 300: G454–G460, 2011. First published December 9, 2010; doi:10.1152/ajpgi.00458.2010. —Cancer-related inflammation recently has been proposed as a major physiological hallmark of malignancy. Some genetic alterations known to promote cellular proliferation and induce malignant transformation also may participate in an intrinsic inflammatory pathway that produces a cancer-promoting inflammatory microenvironment. Little is known about this intrinsic inflammatory pathway in Barrett’s esophagus. We have used a series of nontransformed and transformed human Barrett’s epithelial cell lines developed in our laboratory to explore the potential contribution of interleukin (IL)-6 and signal transducer and activator of transcription (STAT3) (key molecules in the intrinsic inflammatory pathway) to Barrett’s carcinogenesis. We determined IL-6 mRNA expression and protein secretion and protein expression of activated phospho-STAT3 and its downstream target myeloid cell leukemia (mcl)-1 (Mcl-1). We used an IL-6 blocking antibody and two JAK kinase inhibitors (AG490 and JAK inhibitor I) to assess whether STAT3 activation is IL-6 dependent. We also used small interfering RNAs (siRNAs) to STAT3 and Mcl-1 to assess effects of STAT3 pathway inhibition on apoptosis. Phospho-STAT3 was expressed only by transformed Barrett’s cells, which also exhibited higher levels of IL-6 mRNA and of IL-6 and Mcl-1 proteins than nontransformed Barrett’s cells. STAT3 phosphorylation could be blocked by IL-6 blocking antibody and by AG490 and JAK inhibitor I. In transformed Barrett’s cells, rates of apoptosis following exposure to deoxycholic acid were significantly increased by transfection with siRNAs for STAT3 and Mcl-1. We conclude that activation of the IL-6/STAT3 pathway in transformed Barrett’s epithelial cells enables them to resist apoptosis. These findings demonstrate a possible contribution of the intrinsic inflammatory pathway to carcinogenesis in Barrett’s esophagus.

Barrett’s esophagus; malignant transformation

CHRONIC GASTROESOPHAGEAL REFLUX DISEASE (GERD) can cause inflammation of the esophageal mucosa, a condition called reflux esophagitis. In some cases, reflux esophagitis heals with the replacement of reflux-damaged esophageal squamous cells by intestinal-type, columnar cells, resulting in the metaplastic condition called Barrett’s esophagus (20). Barrett’s metaplasia is predisposed to the development of esophageal adenocarcinoma for reasons that remain unclear. Chronic inflammation is known to contribute to cancer development, and chronic reflux esophagitis is judged to play a role in promoting the neoplastic progression of Barrett’s esophagus.

Recently, it has been proposed that the link between inflammation and cancer can involve two pathways: 1) the familiar extrinsic pathway in which clinical disorders like GERD cause local tissue inflammation that contributes to carcinogenesis; and 2) an intrinsic pathway in which the genetic abnormalities acquired by precancerous cells produce an inflammatory tumor microenvironment that contributes to neoplastic progression (16). Patients with Barrett’s esophagus usually are treated with acid-suppressing medications like proton pump inhibitors, a clinical strategy aimed exclusively at the extrinsic inflammatory pathway (GERD) in Barrett’s carcinogenesis. Little is known about the role of the intrinsic inflammatory pathway in Barrett’s esophagus and, consequently, there are no clinical strategies aimed at this potentially important therapeutic target.

A key concept of the intrinsic cancer-related inflammation pathway is that some of the same genetic events that endow the cancer cell with growth advantages also produce an inflammatory microenvironment (16). In human papillary thyroid cancer, for example, alterations in RET (rearranged during transfection), a key growth-promoting gene that encodes a protein tyrosine kinase, have been found to activate an “inflammatory program” that results in the expression of inflammatory chemokines, chemokine receptors, cytokines, matrix-degrading enzymes, and adhesion molecules (2). Other oncoproteins such as Ras and MYC, which are activated in a number of human tumors, also induce the production of tumor-promoting inflammatory cytokines (reviewed in Ref. 16). The inflammatory environment also can be influenced by inactivation of tumor suppressor genes such as von Hippel-Lindau, transforming growth factor-β, and phosphatase and tensin homolog (PTEN) (reviewed in Ref. 16). Thus a number of genetic alterations that promote cellular proliferation also can promote inflammation.

Some of the key molecules involved in cancer-related inflammation are transcription factors such as signal transducer and activator of transcription (STAT) 3, and cytokines such as interleukin (IL)-6 (3). However, it is not clear which component(s) of the intrinsic cancer-related inflammation program contribute importantly to carcinogenesis.

Recently, we induced the malignant transformation of telomerase-immortalized, p16-deficient, human Barrett’s epithelial cells by knocking down the p53 pathway and activating the oncogenic Ras pathway (12, 23). In the process, we developed a number of nontransformed cell lines that have well-defined, growth-promoting genetic changes that appear to recapitulate various stages of neoplastic progression in Barrett’s esophagus. Using these cell lines, we have explored the contribution of

Address for reprint requests and other correspondence: R. F. Souza, Dept. of GI, MC# 111B1, Dallas VA Medical Center, 4500 South Lancaster Rd., Dallas, TX 75216 (e-mail: rhonda.souza@utsouthwestern.edu).
two key molecules in the intrinsic inflammatory pathway (IL-6 and STAT3) to Barrett’s carcinogenesis.

METHODS

Cell culture. We used a series of nontransformed and transformed Barrett’s epithelial cell lines developed in our laboratory (12, 23). In brief, we started with a telomerase-immortalized, p16-deficient Barrett’s epithelial cell line (BAR-T) that we had established from endoscopic biopsy specimens of nondysplastic Barrett’s metaplasia. The BAR-T cells were infected with the retroviral vector pSUPER-RNAi-p53 (OligoEngine, Seattle, WA) to knock down p53, the retroviral vector pBabe-H-RasG12V to express human oncogenic H-RasG12V (obtained from Dr. Robert Weinberg, Whitehead Institute, Cambridge, MA) (15), or the combination of both as previously described (23). Through these experiments, we generated BAR-T cells containing 1) pSUPER-p53RNAi (not transformed); 2) pBabe-H-RasG12V-zeocin (not transformed); and 3) pSUPER-p53RNAi and pBabe-H-RasG12V-zeocin (transformed). The nontransformed BAR-T, BAR-T p53RNAi, and BAR-T H-RasG12V-expressing (clone R6 and R7) cell lines were cocultured with a fibroblast feeder layer as previously described (12, 19). The transformed BAR-T p53RNAi H-RasG12V-expressing cell lines (clones R1 and R2) could be cultured without a fibroblast feeder layer. All cell lines were maintained in monolayer culture at 37°C in humidified air with 5% CO2 in growth media as previously described. For individual experiments, the nontransformed cell lines were equally seeded into collagen IV-coated wells (BD Biosciences, San Jose, CA), whereas the transformed cell lines were equally seeded onto standard culture dishes.

Western blotting. Cells were washed in cold PBS followed by immediate cell lysis. Cells were lysed in 1× cell lysis buffer (Cell Signaling Technology, Beverly, MA); equal amounts of protein were separated by SDS-polyacrylamide gel electrophoresis; protein concentrations were determined using the BCA-200 protein assay kit (Pierce, Rockford, IL). After separation and transfer to nitrocellulose membranes, the membranes were incubated with primary antibodies. Primary antibodies used for Western blot were total Stat3 and phospho-Stat3 (Tyr705) (D3A7) (both from Cell Signaling Technology), myeloid cell leukemia (mcl)-1 (Mcl-1) (from Santa Cruz Biotechnology, Santa Cruz, CA), and anti-β-actin (Sigma-Aldrich, St. Louis, MO). Horseradish peroxidase secondary antibodies were used and chemiluminescence was determined by using the Super Signal West Dura detection system (Pierce); β-actin or β-tubulin was used to confirm equal loading. All Western blots were performed in duplicate. Densitometry was performed by using the Multi Analyst software package (Bio-Rad, Hercules, CA). Results were expressed as relative intensity units and normalized to β-actin or β-tubulin.

Reverse transcription-PCR. Total cellular RNA was extracted with TRIzol (Invitrogen) according to the manufacturer’s instructions. The samples were DNase treated and the first strand cDNA was synthesized by using M-MLV reverse transcriptase (Invitrogen) per the manufacturer’s instructions. The sequences of primers for IL-6, IL-6R, and gp130 were 1) IL-6 (forward) 5’-CATGTGTGAAAGCAGCAAAGAGGC-3’ and IL-6 (reverse) 5’-CACCAGGCAAGTCTCCTCATTGAA-3’, 112 bp; 2) IL-6R (forward) 5’-CCTGCCAACATCACAGTCACTG-3’ and IL-6R (reverse) 5’-TTTGACCGTTCAGCCCGAT-3’, 134 bp; and 3) gp130 (forward) 5’-AGAGGAGCGGCCAGAAGATCTA-3’ and gp130 (reverse) 5’-GACTGGATTTCATGCTGACTGCA-3’, 110 bp. PCR was performed by using GoTaq DNA polymerase (Promega, Madison, WI) according to the manufacturer’s instructions using the

A

B

C

Fig. 1. Phospho-STAT3 and Mcl-1 expression are increased in transformed, but not in nontransformed BAR-T cells. A: Western blot for phospho-STAT3, total STAT3, and Mcl-1. Note the expression of phospho-STAT3 only in the transformed Barrett’s cells, which also express higher levels of Mcl-1. β-Tubulin served as a loading control. Bar graphs show the results of densitometry depicted as mean (+SE) relative intensity units (RIUs, normalized to β-tubulin) for p-STAT3 (B) and Mcl-1 (C) expression from 2 individual experiments. siRNA, small interfering RNA.
Inhibition of the IL-6/STAT3 signaling pathway. Equally seeded wells of cells were placed in KBM-2 media without growth factors or serum for 1, 4, and 24 h, after which STAT3 phosphorylation levels were determined. To inhibit IL-6–mediated activation of STAT3, cells were cultured in KBM-2 media without growth factors or serum for 4 h in the presence of an IL-6 blocking antibody (2 μg/ml; R&D Systems, Minneapolis, MN) followed by the detection of STAT3 phosphorylation levels; a mouse IgG antibody (2 μg/ml) was used as a control. To inhibit the JAK kinases, we used two different pharmacological inhibitors, AG490 and JAK inhibitor I (Calbiochem, San Diego, CA); JAK inhibitor I, a pan-JAK inhibitor has been shown to be more specific and sensitive than AG490 (18, 22). Transformed Barrett’s cells were treated with either 50 or 100 μM AG490 for 24 h, or 10 μM of the JAK inhibitor I for durations ranging from 3–24 h, and STAT3 phosphorylation levels and expression of Mcl-1 were assayed. Since pharmacological agents can have nonspecific effects, we determined the role of STAT3 in mediating effects on apoptosis using a specific STAT3 siRNA. We also used a specific siRNA against Mcl-1, a downstream STAT3 target gene implicated in apoptotic resistance. Cells were equally plated in 6- or 24-well tissue culture plates. After 24 h, the cells were transfected using Lipofectamine 2000 (Invitrogen) with 20 nM of the siGenome SMART pool STAT3 or Mcl-1 siRNA (Thermo Scientific, Waltham, MA), per the manufacturer’s instructions. 48 h after transfection, cells were treated with 250 μM DCA. As a control, cells were transfected with siGenome NonTargeting siRNA no. 2 (Thermo Scientific). All experiments were performed in duplicate.

Statistical analyses. Quantitative data are expressed as means + SE. Statistical analysis was performed using an unpaired Student’s t-test or an ANOVA and the Student-Newman-Keuls multiple-comparison test with the Instat for Windows statistical software package (GraphPad Software, San Diego, CA). P values <0.05 were considered significant for all analyses.

RESULTS

Expression of phospho-STAT3 (Tyr705) is increased in transformed, but not in nontransformed, Barrett’s epithelial cells. NF-κB and STAT3 are key transcription factors in cancer-related inflammation. NF-κB is well known to mediate inflammation and tumor progression, and we have previously found that activation of NF-κB causes resistance to apoptosis in Barrett’s epithelial cells (10). In these experiments, we focused on STAT3 and explored its activation in our cell lines by performing Western blotting for phospho-STAT3 and Mcl-1, a survival protein that is a downstream target of STAT3. We found similar levels of expression for total STAT3 in all of our cell lines (transformed and nontransformed). In contrast, expression of phospho-STAT3 was detected only in the transformed Barrett’s cells, which also expressed higher levels of Mcl-1 (Fig. 1). These data suggest that the STAT3 pathway is active in transformed, but not in nontransformed, Barrett’s epithelial cells.

IL-6 mRNA levels and protein secretion are increased in transformed Barrett’s epithelial cells. IL-6 is a key cytokine that has been implicated in cancer-related inflammation, andSTAT3 is the main downstream effector molecule for IL-6. Therefore, we determined whether mRNA levels of IL-6 and its receptors (IL-6R and gp130) were increased in our transformed Barrett’s cells. We found similar levels of expression for IL-6R and gp130 mRNAs in all of our cell lines (Fig. 2A). In contrast, only the transformed Barrett’s cells expressed high levels of IL-6 mRNA. We also determined levels of IL-6 protein in the media of the cells and found that those levels
were significantly higher in the transformed Barrett’s cells (Fig. 2B).

**STAT3 activation in transformed Barrett’s cells is dependent on IL-6/JAK signaling.** STAT3 activation in tumors can be either dependent on or independent of IL-6 signaling (reviewed in Ref. 8). To determine whether STAT3 phosphorylation is IL-6 dependent in our transformed Barrett’s cells, we explored the time course for IL-6 secretion in BAR-T p53 RNAi+ H-RasG12V+ clone 1. Fresh media was placed on the transformed Barrett’s cells and then collected 4 and 24 h later. We found that levels of IL-6 in the media significantly increased in a time-dependent manner, as did the levels of phospho-STAT3 expression (Fig. 3, A and B). Treatment with an IL-6 blocking antibody (2 μg/ml) caused a marked decrease in STAT3 phosphorylation, suggesting that activation of STAT3 is dependent on IL-6 signaling in transformed Barrett’s cells (Fig. 3C).

Activation and phosphorylation of the gp130 receptor subunit by IL-6 causes activation of the JAK tyrosine kinases, which in turn phosphorylate STAT3. To further demonstrate that STAT3 phosphorylation is IL-6 dependent, we treated our transformed Barrett’s cell line with two different JAK inhibitors (18, 22). As shown in Fig. 4A, AG490 caused a dose-dependent decrease in STAT3 phosphorylation and Mcl-1 expression. JAK inhibitor I also decreased STAT3 phosphorylation by 3 h (an effect that persisted at 24 h) and decreased Mcl-1 protein expression by 24 h (Fig. 4B). Taken together, these data suggest that STAT3 activation in transformed Barrett’s cells is indeed dependent on IL-6/JAK signaling.

**Inhibition of STAT3 sensitizes transformed Barrett’s cells to bile acid-induced apoptosis.** Having found activation of STAT3 and expression of its downstream antiapoptotic protein (Mcl-1) in transformed Barrett’s cells, we next sought to determine whether activation of STAT3 contributes to apoptotic resistance. We inhibited STAT3 activity by transfecting transformed Barrett’s cells (BAR-T p53 RNAi+ H-RasG12V+ clone 1) with a STAT3 siRNA. The bile acid DCA has been shown to induce apoptosis in Barrett’s epithelial cells and cancer cells (4). Therefore, we treated cells with 250 μM DCA for 3 h, after which apoptosis was determined by a Cell Death ELISA assay. To determine the efficiency of STAT3 siRNA on inhibiting STAT3 expression, Western blotting was performed at 48 and 72 h following transfection. We found a decrease in total STAT3 expression and a complete loss of phospho-STAT3 expression following transfection with STAT3 siRNA at both time points; in contrast, total STAT3 expression was unchanged and phospho-STAT3 expression was slightly increased at both time points in cells containing a control siRNA (Fig. 5A). As expected, treatment with DCA caused a significant increase in apoptosis in transformed Barrett’s cells containing the control siRNA (Fig. 5B). In the STAT3-knockdown cells, treatment with DCA caused a significantly greater increase in apoptosis than in the control cells (Fig. 5B). These observations suggest that STAT3 activation contributes to apoptotic resistance in transformed Barrett’s cells.

**Inhibition of Mcl-1 sensitizes transformed Barrett’s cells to bile acid-induced apoptosis.** We next sought to determine whether expression of Mcl-1, the downstream target of STAT3, contributes to the apoptotic resistance of transformed Barrett’s cells. We transfected BAR-T p53 RNAi+ H-RasG12V+ clone 1 with Mcl-1 siRNA oligonucleotides and determined the rates of apoptosis following treatment with 250 μM DCA for 3 h. To determine the efficiency of siRNA for inhibiting Mcl-1 expression, Western blotting was performed. We noted complete elimination of Mcl-1 expression 48 h after transfection with the Mcl-1 siRNA; Mcl-1 expression was unchanged in transformed cells containing a control siRNA (Fig. 6A). We found that transfection of the transformed Barrett’s cells with siRNA against Mcl-1 significantly increased basal rates of apoptosis in the Mcl-1 knockdown cells (Fig. 6B). In agreement with our earlier findings, treatment with DCA caused an
increase in apoptosis in cells containing the control siRNA (Fig. 6B). In the Mcl-1 knockdown cells, treatment with DCA caused a significantly greater increase in apoptosis than in cells containing control siRNA (Fig. 6B). These findings suggest that Mcl-1 contributes to apoptotic resistance in transformed Barrett’s cells.

DISCUSSION

In earlier experiments, we induced the malignant transformation of benign Barrett’s epithelial cells in vitro through the stepwise disruption of several key growth regulatory pathways including the p16/Rb and p53 checkpoint arrest pathways, the mitogenic Ras signaling pathway, and the telomerase-dependent replicative senescence pathway (23). As a result of these experiments, we established a series of transformed and nontransformed Barrett’s epithelial cell lines with well-defined genetic alterations similar to those that have been described in esophageal biopsy specimens from patients with various stages of neoplasia in Barrett’s esophagus. In the present experiments, we used our unique cell lines to explore the role of the recently proposed 7th hallmark of cancer, cancer-related inflammation, in Barrett’s carcinogenesis. The active, phosphorylated form of STAT3 has been demonstrated in biopsy specimens of dysplastic Barrett’s epithelia and in esophageal adenocarcinoma (4). Moreover, phospho-STAT3 expression levels have been found to increase as the severity of dysplasia increases, suggesting that our findings in vitro reflect in vivo neoplastic processes (4). Thus signaling via STAT3 may contribute to the link between inflammation and carcinogenesis in Barrett’s esophagus.

TNF-α, IL-1β, and IL-6 are among the key inflammatory cytokines implicated in carcinogenesis (3). Inflamed Barrett’s epithelium has been found to express proinflammatory cytokines including IL-1β and IL-8 (6, 17). Moreover, the infiltrating inflammatory cells may not be the sole source of these cytokines, because Barrett epithelial cells have been shown to express IL-8, IL-1β, and IL-10 (7, 17). In preliminary studies, we found no increase in the secretion of TNF-α, IL-1β, and IL-8 as Barrett’s cells were transformed in vitro (data not shown).
IL-6 is a potent inflammatory cytokine that appears to play a key role in cancer growth and metastasis (13). IL-6 signals via a receptor complex comprised of IL-6R and glycoprotein 130 (gp130) (13). Activation of this complex causes gp130 to phosphorylate and thereby activate the Janus (JAK) kinases 1 and 2 (9, 13, 14). Subsequent phosphorylation of STATs by JAKs results in activation of specific target genes implicated in carcinogenesis including Mcl-1 (1). We found similar levels of mRNA expression for IL-6 receptors (IL-6R and gp130) in our transformed and nontransformed Barrett’s cell lines. In contrast, only the transformed Barrett’s cells exhibited a significant increase in IL-6 mRNA and protein secretion. Biopsy specimens of Barrett’s metaplasia have been shown to exhibit higher levels of IL-6 mRNA and protein secretion than normal esophageal squamous epithelium, and these levels were found to be highest in one specimen from an esophageal adenocarcinoma (5).

IL-6 signaling in transformed Barrett’s cells. To confirm this, we treated our transformed Barrett’s cell line with two different JAK inhibitors (AG490 and JAK inhibitor I, a pan-JAK inhibitor found to be more specific and sensitive than AG490) (18, 22). Treatment with AG490 induced a dose-dependent decrease in IL-6 secretion and STAT3 phosphorylation. Moreover, STAT3 phosphorylation could be markedly decreased by treatment with an IL-6 blocking antibody, suggesting that activation of STAT3 indeed is dependent on IL-6 signaling.

IL-6 production by the cells is secreted into the extracellular space, where it binds to its receptor complex (IL-6R and gp130). This recruits JAKs to the receptor complex, where they phosphorylate gp130. This allows STATs to dock on the receptor where they, in turn, are phosphorylated. Dimerization of the phospho-STATs enables them to translocate into the nucleus where they bind to promoters to initiate the transcription of target genes such as Mcl-1 (a potent antiapoptotic gene). Expression of Mcl-1 allows the cells to resist bile acid-induced apoptosis.

Fig. 5. Inhibition of STAT3 increases deoxycholic acid (DCA)-induced apoptosis in transformed Barrett’s cells. A: Western blots for phospho-STAT3 and total STAT3 in control cells (without siRNA transfection), cells transfected with control siRNA, and cells transfected with STAT3 siRNA. Note that STAT3 siRNA decreases total STAT3 protein expression and eliminates phospho-STAT3 expression at 48 and 72 h. B: rates of apoptosis in cells transfected with control siRNA and in cells transfected with STAT3 siRNA at baseline and after treatment with 250 μM DCA for 3 h. Bar graphs depict means ± SE from 1 of 2 individual experiments. *P < 0.001 compared with control siRNA containing cells; +P < 0.001 compared with DCA-treated control siRNA containing cells.

Fig. 6. Inhibition of Mcl-1 increases apoptosis in transformed Barrett’s cells. A: Western blots for Mcl-1 in cells transfected with control siRNA and in cells transfected with Mcl-1 siRNA. Note that Mcl-1 siRNA eliminates Mcl-1 protein expression at 48 h. B: rates of apoptosis in cells transfected with control siRNA and in cells transfected with Mcl-1 siRNA at baseline and after treatment with 250 μM DCA for 3 h. Bar graphs depict means ± SE from 1 of 2 individual experiments. *P < 0.001 compared with control siRNA containing cells; **P < 0.001 compared with control siRNA containing cells; +P < 0.001 compared with DCA-treated control siRNA containing cells.

Fig. 7. Schematic representation of how IL-6 and STAT3 mediate apoptotic resistance in transformed Barrett’s epithelial cells. IL-6 produced by the cells is secreted into the extracellular space, where it binds to its receptor complex (IL-6Rα and gp130). This recruits JAKs to the receptor complex, where they phosphorylate gp130. This allows STATs to dock on the receptor where they, in turn, are phosphorylated. Dimerization of the phospho-STATs enables them to translocate into the nucleus where they bind to promoters to initiate the transcription of target genes such as Mcl-1 (a potent antia apoptotic gene). Expression of Mcl-1 allows the cells to resist bile acid-induced apoptosis.
in STAT3 phosphorylation and Mcl-1 expression; treatment with the JAK inhibitor I decreased STAT3 phosphorylation as early as 3 h and Mcl-1 protein expression by 24 h. Taken together, these data demonstrate that STAT3 activation in transformed Barrett’s cells is dependent on IL-6/JAK signaling.

STAT3 target genes are known to regulate many of the physiological processes involved in tumorigenesis including cell cycle progression, apoptosis, tumor angiogenesis, invasion, and metastasis (1). Mcl-1 is an antiapoptotic member of the Bcl-2 family and is a known downstream target gene of STAT3 (21). Biopsy specimens of Barrett’s metaplasia demonstrate higher phospho-STAT3 expression and a greater intensity of Mcl-1 protein expression than normal esophageal squamous or duodenal epithelia (5). In our transformed Barrett’s cells, we found that inhibition of IL-6/STAT3 signaling with either the IL-6 blocking antibody or the JAK inhibitors also blocked Mcl-1 expression, suggesting that Mcl-1 is a STAT3 target gene in our transformed cell lines.

To demonstrate that IL-6/STAT3 signaling is physiologically relevant in transformed Barrett’s epithelial cells, we transfected the cells with siRNAs against STAT3 or Mcl-1 and determined their ability to resist apoptosis. We treated the cells with unconjugated DCA at a dose and duration previously shown to induce apoptosis in Barrett’s epithelial cells and cancer cells (4). We found that transfection of the transformed cells with either of these siRNAs significantly increased DCA-induced apoptosis, suggesting that the STAT3/Mcl-1 pathway mediates apoptotic resistance of transformed Barrett’s cells (Fig. 7). Further studies are warranted to elucidate other specific proteins regulated by STAT3 that may be involved in Barrett’s tumorigenesis.

In conclusion, we have shown that the same genetic events that induce the malignant transformation of p16-deficient, telomerase-immortalized Barrett’s epithelial cells (i.e., knockdown of p53 and expression of oncogenic H-Ras) also are associated with activation of the IL-6/STAT3 pathway. We have demonstrated that inhibitors of STAT3 and Mcl-1 can significantly increase the rates of DCA-induced apoptosis in transformed Barrett’s cells, suggesting that STAT3 signaling is physiologically relevant in those cells. These findings support a role for the intrinsic inflammatory pathway in Barrett’s carcinogenesis and suggest that the IL-6/STAT3 pathway may be a novel target for chemoprevention in Barrett’s esophagus.

GRANTS

This work was supported by the Office of Medical Research, Department of Veterans Affairs (R. F. Souza, S. J. Spechler) and the National Institutes of Health (R01-DK63621 to R. F. Souza, R01-CA134571 to R. F. Souza and S. J. Spechler).

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the author(s).

REFERENCES